Publications 2023

Lundgren JD, Babiker AG, Sharma S, Grund B, Phillips AN, Matthews G, Kan VL, Aagaard B, Abo I, Alston B, Arenas-Pinto A, Avihingsanon A, Badal-Faesen S, Brites C, Carey C, Casseb J, Clarke A, Collins S, Corbelli GM, Dao S, Denning ET, Emery S, Eriobu N, Florence E, Furrer H et al. (2023)
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection
NEJM Evid, 2 (3)
DOI 10.1056/evidoa2200302, PubMed 37213438

Publications 2020

Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, Tonby K, Barratt-Due A, Sokolova M, Schjalm C, Chaban V, Kolderup A, Tran T, Tollefsrud Gjølberg T, Skeie LG, Hesstvedt L, Ormåsen V, Fevang B, Austad C, Müller KE, Fladeby C, Holberg-Petersen M, Halvorsen B, Müller F, Aukrust P et al. (2020)
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
Proc Natl Acad Sci U S A, 117 (40), 25018-25025
DOI 10.1073/pnas.2010540117, PubMed 32943538

Trøseid M, Lutro O, Ormaasen V (2020)
[Experimental treatment for COVID-19 should be undertaken in randomised studies]
Tidsskr Nor Laegeforen, 140 (7)
DOI 10.4045/tidsskr.20.0282, PubMed 32378863

Publications 2019

Quist-Paulsen E, Kran AB, Lindland ES, Ellefsen K, Sandvik L, Dunlop O, Ormaasen V (2019)
To what extent can clinical characteristics be used to distinguish encephalitis from encephalopathy of other causes? Results from a prospective observational study
BMC Infect Dis, 19 (1), 80
DOI 10.1186/s12879-018-3570-2, PubMed 30669985

Quist-Paulsen E, Ormaasen V, Kran AB, Dunlop O, Ueland PM, Ueland T, Eikeland R, Aukrust P, Nordenmark TH (2019)
Encephalitis and aseptic meningitis: short-term and long-term outcome, quality of life and neuropsychological functioning
Sci Rep, 9 (1), 16158
DOI 10.1038/s41598-019-52570-2, PubMed 31695095

Publications 2018

Mocroft A, Laut K, Reiss P, Gatell J, Ormaasen V, Cavassini M, Hadziosmanovic V, Mansinho K, Pradier C, Vasylyev M, Mitsura V, Vandekerckhove L, Ostergaard L, Clarke A, Degen O, Mulcahy F, Castagna A, Sthoeger Z, Flamholc L, Sedláček D, Mozer-Lisewska I, Lundgren JD, EuroSIDA Study (2018)
Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?
AIDS, 32 (2), 205-215
DOI 10.1097/QAD.0000000000001684, PubMed 29112060

Quist-Paulsen E, Aukrust P, Kran AB, Dunlop O, Ormaasen V, Stiksrud B, Midttun Ø, Ueland T, Ueland PM, Mollnes TE, Dyrhol-Riise AM (2018)
High neopterin and IP-10 levels in cerebrospinal fluid are associated with neurotoxic tryptophan metabolites in acute central nervous system infections
J Neuroinflammation, 15 (1), 327
DOI 10.1186/s12974-018-1366-3, PubMed 30470234

Ursin Rein P, Jacobsen D, Ormaasen V, Dunlop O (2018)
Pneumococcal sepsis requiring mechanical ventilation: Cohort study in 38 patients with rapid progression to septic shock
Acta Anaesthesiol Scand, 62 (10), 1428-1435
DOI 10.1111/aas.13236, PubMed 30132782

Publications 2015

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M et al. (2015)
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
Clin Infect Dis, 62 (5), 655-663
DOI 10.1093/cid/civ963, PubMed 26620652

Publications 2014

Llibre JM, Cozzi-Lepri A, La Rosa JA, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura VM, Ormaasen V, Maltez F, Beniowski M, Paredes R, Eurosida in Eurocoord (2014)
Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
J Int AIDS Soc, 17 (4 Suppl 3), 19810
DOI 10.7448/IAS.17.4.19810, PubMed 25397554

Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD, EuroSIDA in EuroCOORD (2014)
Deteriorating renal function and clinical outcomes in HIV-positive persons
AIDS, 28 (5), 727-37
DOI 10.1097/QAD.0000000000000134, PubMed 24983543

Publications 2013

Andersson LM, Vesterbacka J, Blaxhult A, Flamholc L, Nilsson S, Ormaasen V, Sönnerborg A, Gisslén M (2013)
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial
Scand J Infect Dis, 45 (7), 543-51
DOI 10.3109/00365548.2012.756985, PubMed 23294034

Publications 2012

Quist-Paulsen E, Kran AM, Dunlop O, Wilson J, Ormaasen V (2012)
Infectious encephalitis: a description of a Norwegian cohort
Scand J Infect Dis, 45 (3), 179-85
DOI 10.3109/00365548.2012.719634, PubMed 23113672

Rekić D, Röshammar D, Bergstrand M, Tarning J, Calcagno A, D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Äbelö A (2012)
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients
AAPS J, 15 (2), 308-15
DOI 10.1208/s12248-012-9440-8, PubMed 23224752

Publications 2011

Rekić D, Clewe O, Röshammar D, Flamholc L, Sönnerborg A, Ormaasen V, Gisslén M, Abelö A, Ashton M (2011)
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy
AAPS J, 13 (4), 598-605
DOI 10.1208/s12248-011-9299-0, PubMed 21913053

Röshammar D, Simonsson US, Ekvall H, Flamholc L, Ormaasen V, Vesterbacka J, Wallmark E, Ashton M, Gisslén M (2011)
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients
J Pharmacokinet Pharmacodyn, 38 (6), 727-42
DOI 10.1007/s10928-011-9217-1, PubMed 21964996

Publications 2010

Bratholm C, Johannessen A, Naman E, Gundersen SG, Kivuyo SL, Holberg-Petersen M, Ormaasen V, Bruun JN (2010)
Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital
J Antimicrob Chemother, 65 (9), 1996-2000
DOI 10.1093/jac/dkq234, PubMed 20576637

Edén A, Andersson LM, Andersson O, Flamholc L, Josephson F, Nilsson S, Ormaasen V, Svedhem V, Säll C, Sönnerborg A, Tunbäck P, Gisslén M (2010)
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients
AIDS Res Hum Retroviruses, 26 (5), 533-40
DOI 10.1089/aid.2009.0177, PubMed 20455766

Grydeland H, Walhovd KB, Westlye LT, Due-Tønnessen P, Ormaasen V, Sundseth Ø, Fjell AM (2010)
Amnesia following herpes simplex encephalitis: diffusion-tensor imaging uncovers reduced integrity of normal-appearing white matter
Radiology, 257 (3), 774-81
DOI 10.1148/radiol.10100179, PubMed 20935078

Johannessen A, Holberg-Petersen M, Lövgaarden G, Naman E, Ormaasen V, Matee MI, Gundersen SG, Bruun JN (2010)
HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania
Antivir Ther, 15 (7), 1003-9
DOI 10.3851/IMP1660, PubMed 21041915

Publications 2009

Josephson F, Andersson MC, Flamholc L, Gisslén M, Hagberg L, Ormaasen V, Sönnerborg A, Vesterbacka J, Böttiger Y (2009)
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients
Eur J Clin Pharmacol, 66 (4), 349-57
DOI 10.1007/s00228-009-0763-z, PubMed 19967342

Paraskevis D, Pybus O, Magiorkinis G, Hatzakis A, Wensing AM, van de Vijver DA, Albert J, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Coughlan S, Costagliola D, De Luca A, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hoepelman I, Horban A, Korn K, Kücherer C, Leitner T et al. (2009)
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
Retrovirology, 6, 49
DOI 10.1186/1742-4690-6-49, PubMed 19457244

Publications 2008

Bjark P, Ormaasen V, Skjelmerud T (2008)
[Treatment of erythema migrans]
Tidsskr Nor Laegeforen, 128 (24), 2844
PubMed 19092956

Josephson F, Bertilsson L, Böttiger Y, Flamholc L, Gisslén M, Ormaasen V, Sönnerborg A, Diczfalusy U (2008)
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels
Eur J Clin Pharmacol, 64 (8), 775-81
DOI 10.1007/s00228-008-0492-8, PubMed 18458892

Publications 2007

Jensenius M, Berild D, Ormaasen V, Maehlen J, Lindegren G, Falk KI (2007)
Fatal subarachnoidal haemorrhage in a Norwegian traveller with dengue virus infection
Scand J Infect Dis, 39 (3), 272-4
DOI 10.1080/00365540600891307, PubMed 17366065

Ormaasen V, Sandvik L, Dudman SG, Bruun JN (2007)
HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population
Scand J Infect Dis, 39 (1), 51-7
DOI 10.1080/00365540600904779, PubMed 17366013

Publications 2006

Bruun JN, Skeie L, Maeland A, Dudman SG, Sannes M, Ormaasen V (2006)
[HIV/AIDS--from lethal syndrome to chronic disease]
Tidsskr Nor Laegeforen, 126 (23), 3121-4
PubMed 17160119

Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, Frøland SS, Taskén K (2006)
Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment
AIDS, 20 (6), 813-20
DOI 10.1097/01.aids.0000218544.54586.f1, PubMed 16549964

Ormaasen V, Sandvik L, Rudberg N, Bruun JN (2006)
Serum concentrations of protease inhibitors as predictors of HIV-related clinical events in patients on antiretroviral therapy
Scand J Infect Dis, 38 (8), 650-3
DOI 10.1080/00365540600616993, PubMed 16857610

van de Vijver DA, Wensing AM, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L et al. (2006)
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
J Acquir Immune Defic Syndr, 41 (3), 352-60
DOI 10.1097/01.qai.0000209899.05126.e4, PubMed 16540937

Publications 2005

Ormaasen V (2005)
Studies on mortality, morbidity and predictors of clinical outcome in HIV infected individuals in Oslo: a cohort study 1983-2004
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 293, 1 b. (flere pag.)
BIBSYS 051512637, ISBN 82-8080-142-1

Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L et al. (2005)
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
J Infect Dis, 192 (6), 958-66
DOI 10.1086/432916, PubMed 16107947

Publications 2004

Lugada ES, Mermin J, Asjo B, Kaharuza F, Downing R, Langeland N, Ormaasen V, Bruun J, Awor AC, Ulvestad E (2004)
Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway
Scand J Immunol, 59 (2), 203-8
DOI 10.1111/j.0300-9475.2004.01376.x, PubMed 14871298

Ormaasen V, Sandvik L, Asjø B, Holberg-Petersen M, Gaarder PI, Bruun JN (2004)
An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy
HIV Med, 5 (6), 400-6
DOI 10.1111/j.1468-1293.2004.00244.x, PubMed 15544691

Publications 2003

Ormaasen V, Bruun JN, Sandvik L, Holberg-Petersen M, Gaarder PI (2003)
Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection
Scand J Infect Dis, 35 (6-7), 383-8
DOI 10.1080/00365540310009716, PubMed 12953949

Publications 2002

Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Gargalianos-Kakolyris P, Vella S, Lundgren JD (2002)
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts
J Infect Dis, 186 (2), 189-97
DOI 10.1086/341466, PubMed 12134254

Mørch K, Feruglio SL, Ormaasen V, Bruun JN (2002)
[Severe falciparum malaria treated with exchange transfusion]
Tidsskr Nor Laegeforen, 122 (10), 999-1001
PubMed 12082710

Ormaasen V, Bruun JN, Sandvik L, Holberg-Petersen M, Gaarder PI (2002)
A search for optimal criteria in initiating antiretroviral therapy in chronic human immunodeficiency virus infection focusing on CD4 count and HIV RNA
Scand J Infect Dis, 34 (12), 910-7
DOI 10.1080/0036554021000026957, PubMed 12587624

Publications 2001

Ormaasen V, Brantsaeter AB, Moen EW (2001)
[Tick-borne encephalitis in Norway]
Tidsskr Nor Laegeforen, 121 (7), 807-9
PubMed 11301704

Ormaasen V, Bruun JN (2001)
[Antiviral therapy of HIV infection in adults]
Tidsskr Nor Laegeforen, 121 (29), 3414-20
PubMed 11826789

Ormaasen V, Maeland A (2001)
[Tuberculosis among HIV-infected persons in Norway]
Tidsskr Nor Laegeforen, 121 (29), 3425-30
PubMed 11826791

Svendsen J, Ormaasen V, von der Lippe E, Jacobsen D (2001)
[Two cases of pneumococcal pericarditis]
Tidsskr Nor Laegeforen, 121 (15), 1801-3
PubMed 11464685

Publications 1998

Ormaasen V, Nilsen E, Mortensen L (1998)
[Practical approach to otitis media with methicillin-resistant yellow Staphylococci]
Tidsskr Nor Laegeforen, 118 (26), 4091-2
PubMed 9844514